A Phase 4 interventional study of Rebamipide and optimization of life style in Gastritis, sponsored by BangMao Wang. Completed. Per ClinicalTrials.gov, last updated 2015-03-19.
Sponsored by BangMao Wang · Phase 4, Interventional, and Treatment
To investigate the clinical effect of rebamipide in chronic gastritis patients. Patients with chronic gastritis were randomly divided into the experimental group and the control group. The experimental group were treated with rebamipide 0.1g tid and optimization of life style, and the control group were only optimized their life style for 26 weeks. Upper gastrointestinal endoscopy was performed in all patients to evaluate the severity of gastritis by modified Lanza score (MLS) and the histology by the updated Sydney system before and after treatment.
196 studies on the registry are indexed under Gastritis; 42 are open to participants now.
This study's enrollment of 180 is close to the median of 200 across 113 interventional studies indexed under Gastritis.
Browse Gastritis studies →This is the only study on the registry with BangMao Wang as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
-
The experimental group were treated with rebamipide 0.1g tid and optimization of life style.
Drug: Rebamipide · Behavioral: optimization of life style
The control group were only optimized their life style.
Behavioral: optimization of life style
Rebamipide is a
Also known as: Mucosta
modified Lanza score
Time frame: 26 weeks
visual Analog scale
to describe the inflamamtory of gastric mucosa pathologically
Time frame: 26 weeks
No study locations are listed for this record.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.